Dr. Robert J. Ellis, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Missouri, Kansas City, School of Medicine (1989)
- Years since graduation
- 37
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 597
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1989Medical school: University of Missouri, Kansas City, School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MO license R8N50 -
Medical Oncology Physician
MO license R8N50
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mercy Hospital Springfield Springfield, MO
- Cox Medical Centers Springfield, MO
- Cox Medical Center Branson Branson, MO
- Freeman Health System - Freeman West Joplin, MO
- Lake Regional Health System Osage Beach, MO
Medical groups
- American Oncology PArtners PA (391 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 597
- Services billed
- 171,321
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 15,660 | 12 |
| Injection, pembrolizumab, 1 mg | 13,200 | 11 |
| Injection, aprepitant, 1 mg | 9,490 | 22 |
| Injection, denosumab, 1 mg | 4,440 | 26 |
| Injection, dexamethasone sodium phosphate, 1 mg | 2,504 | 51 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 1,608 | 418 |
| Injection, palonosetron hcl, 25 mcg | 1,070 | 29 |
| Established patient office or other outpatient visit, 20-29 minutes | 872 | 353 |
| Established patient office or other outpatient visit, 30-39 minutes | 477 | 178 |
| Insertion of needle into vein for collection of blood sample | 445 | 225 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Springfield, MO | 182 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Springfield, MO | 124 |
| Hydroxyurea Other prescribers in Springfield, MO | 114 |
| Eliquis (apixaban) Other prescribers in Springfield, MO | 108 |
| Gabapentin Other prescribers in Springfield, MO | 106 |
| Acyclovir Other prescribers in Springfield, MO | 104 |
| Letrozole Other prescribers in Springfield, MO | 84 |
| Ondansetron Hcl Other prescribers in Springfield, MO | 83 |
| Oxycodone Hcl Other prescribers in Springfield, MO | 71 |
| Pomalyst (pomalidomide) | 71 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 16 companies reported 27 payments worth $933 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $285 |
|---|---|
| Aveo Pharmaceuticals, Inc. | $130 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $123 |
| Tempus Ai, Inc | $61.16 |
| Celgene Corporation | $50.17 |
| E.r. Squibb & Sons, L.l.c. | $40.40 |
| Medinc of Texas | $33.53 |
| Stemline Therapeutics Inc. | $30.93 |
| Food and Beverage | $726 |
|---|---|
| Education | $207 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Aveo Pharmaceuticals, Inc. May 25, 2025 | Education FOTIVDA · Oncology · in-kind | $91.40 |
| AstraZeneca Pharmaceuticals LP Nov 25, 2025 | Education ENHERTU · Oncology · in-kind Company’s descriptionJournal Article | $43.25 |
| AstraZeneca Pharmaceuticals LP Nov 13, 2025 | Education IMFINZI · Oncology · in-kind Company’s descriptionJournal Article | $35.06 |
| Aveo Pharmaceuticals, Inc. Mar 17, 2025 | Education FOTIVDA · Oncology · in-kind | $20.00 |
| AstraZeneca Pharmaceuticals LP Dec 4, 2025 | Education IMFINZI · Oncology · in-kind Company’s descriptionJournal Article | $17.22 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 2 companies. The companies reported $108,807 in research payments for these studies, mostly to the institutions running them.
- Investigation-specific Appendix 3 to Master Protocol PLATFORMPANSC2001 (KALEIDOSCOPE) A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Docetaxel Combination Therapy in Metastatic Non-small Cell …
Janssen Research & Development, LLC - A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated…
Janssen Research & Development, LLC - A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line T…
Janssen Research & Development, LLC - A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line T…
Janssen Research & Development, LLC - A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared With OPDIVO (Nivolumab) in Subjects With Treatment-Nave Unresectable or Metastatic Melanoma
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.